Health Services and Pharmacy Practice Research and Innovation, Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, 44150, Thailand.
Master student, Master of Pharmacy Program in Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, 44150, Thailand.
Sci Rep. 2024 Nov 21;14(1):28823. doi: 10.1038/s41598-024-80387-1.
Peripheral artery disease (PAD) patients experience low utility, especially those having undergone amputation. Utility is one of the quality weights of health status, converted from quality of life (QOL). This study aimed to systematically review published literature and analyze a pooled estimate of utility in PAD patients. The following databases were queried for articles published from inception up to August 30, 2022: PubMed, ScienceDirect, Scopus, ThaiJo, and the Thai thesis database. Four quality assessment tools were used, tailored to each study's design. A pooled utility was estimated by the random effect and reported using Rutherford and Fontaine classification systems due to their common use in practice. The protocol was registered with the International Prospective Registration of Systematic Reviews (CRD42023392775). Fourteen high-quality studies were included, pooling utility from 3,664 PAD patients. The pooled utility by the Rutherford categories was 0.67, with scores for categories 0, 1-3, 4, and 5 being 0.88, 0.65, 0.68, and 0.58, respectively. The pooled utility by the Fontaine stage was 0.68, with stages 1, 2, 3, and 4 scoring 0.88, 0.65, 0.67, and 0.58, respectively. PAD utility is comparable to that of other chronic diseases. The pooled utility could be a valuable parameter for cost-utility analysis in PAD management.
外周动脉疾病（PAD）患者的效用较低，尤其是那些已经截肢的患者。效用是健康状况质量权重之一，由生活质量（QOL）转换而来。本研究旨在系统地综述已发表的文献，并分析 PAD 患者效用的汇总估计值。从开始到 2022 年 8 月 30 日，在以下数据库中查询了已发表的文章：PubMed、ScienceDirect、Scopus、ThaiJo 和泰国论文数据库。使用了四种质量评估工具，根据每个研究的设计进行了定制。通过随机效应估计汇总效用，并根据其在实践中的常见用途，使用 Rutherford 和 Fontaine 分类系统进行报告。该方案在国际前瞻性系统评价注册库（CRD42023392775）中进行了注册。纳入了 14 项高质量研究，汇总了 3664 名 PAD 患者的效用。按 Rutherford 分类的汇总效用为 0.67，分类 0、1-3、4 和 5 的评分分别为 0.88、0.65、0.68 和 0.58。按 Fontaine 分期的汇总效用为 0.68，分期 1、2、3 和 4 的评分分别为 0.88、0.65、0.67 和 0.58。PAD 的效用可与其他慢性疾病相媲美。汇总效用可以成为 PAD 管理中成本效用分析的有价值参数。
